Medicure’s Long-Term Market Cap Chart

The last time Medicure (TSXV: MPH) launched FDA Phase 3 trials in November 2006, its market cap over the following twelve months ranged from US$112.60 million up to US$185.06 million. MPH is in FDA Phase 3 trials right now and this time MPH will get approval. MPH’s market cap is only US$27.71 million. MPH will become the market’s #1 largest overall percentage gainer of the next twelve months:

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.